Literature DB >> 18070089

Adiponectin and visfatin concentrations in children treated with valproic acid.

Markus Rauchenzauner1, Edda Haberlandt, Sabine Scholl-Bürgi, Barbara Ernst, Fritz Hoppichler, Daniela Karall, Christoph F Ebenbichler, Kevin Rostasy, Gerhard Luef.   

Abstract

Chronic antiepileptic therapy with valproic acid (VPA) is associated with increased body weight and insulin resistance in adults and children. Attempts to determine the underlying pathophysiologic mechanisms have failed. Adipocytokines have recently been defined as a link between glucose and fat metabolism. We herein demonstrate that VPA-associated overweight is accompanied by lower adiponectin and higher leptin concentrations in children. The absence of any relationship with visfatin concentration does not suggest a role of this novel insulin-mimetic hormone in VPA-associated metabolic alterations. Therefore, adiponectin and leptin but not visfatin may be considered as potential regulators of glucose and fat metabolism during VPA-therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18070089     DOI: 10.1111/j.1528-1167.2007.01460.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  3 in total

1.  Plasma leptin, neuropeptide Y, ghrelin, and adiponectin levels and carotid artery intima media thickness in epileptic children treated with valproate.

Authors:  Huseyin Tokgoz; Kursad Aydin; Bulent Oran; Aysel Kiyici
Journal:  Childs Nerv Syst       Date:  2012-05-30       Impact factor: 1.475

Review 2.  Impact of Antiseizure Medications on Appetite and Weight in Children.

Authors:  Ersida Buraniqi; Hicham Dabaja; Elaine C Wirrell
Journal:  Paediatr Drugs       Date:  2022-05-21       Impact factor: 3.022

3.  The Effect of the Ketogenic Diet on Adiponectin, Omentin and Vaspin in Children with Drug-Resistant Epilepsy.

Authors:  Marcin Chyra; Wojciech Roczniak; Elżbieta Świętochowska; Magdalena Dudzińska; Joanna Oświęcimska
Journal:  Nutrients       Date:  2022-01-22       Impact factor: 5.717

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.